Long-term enzyme replacement therapy for patients w/ confirmed diagnosis of type 1 or 3 Gaucher disease & who exhibit ≥1 clinically significant non-neurological manifestations of anemia, thrombocytopenia, bone disease, hepatomegaly or splenomegaly.
Hypersensitivity reactions in patients w/ Ab to imiglucerase. Periodically monitor for IgG Ab formation in patients suspected of decreased response. Patients on controlled Na diet. Pregnancy & lactation.
Sign Out
